News

Ajanta Pharma Q4FY21 consolidated PAT drops QoQ to Rs. 159.26 Cr

The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021

  • By IPP Bureau | May 03, 2021

Ajanta Pharma has reported total income of Rs.759.37 crores during the period ended March 31, 2021 as compared to Rs.754.22 crores during the period ended December 31, 2020 and a total income of Rs.738.65 crores during the period ended March 31, 2020.

Ajanta Pharma has posted net profit of Rs.159.26 crores for the period ended March 31, 2021 as against net profit of Rs.176.63 crores for the period ended December 31, 2020 and Rs.129.16 crores for the period ended March 31, 2020.

Ajanta Pharma has reported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021 as compared to Rs.2680.06 crores during the 12 months period ended March 31, 2020.

Ajanta Pharma has posted net profit / (loss) of Rs.653.87 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.467.70 crores for the 12 months period ended March 31, 2020.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.